Stock report · Delisted · Nasdaq
LakeShore Biopharma Co., Ltd (LSB)
0.83USD Delisted Final close · Nov 21, 2025
LSB no longer trades. LakeShore Biopharma was delisted from the Nasdaq in November 2025.
All prices on this page are historical. The last trade was on November 21, 2025, at $0.83.
LSB stock price history
Final trading statistics
- Final close
- $0.83
- Final trading day
- Nov 21, 2025
- Market cap at delisting
- $34.21M
- Shares outstanding
- 41.21M
- Final 52-week range
- $0.30 – $3.99
- Avg. volume (final 3 mo.)
- 39,524
- All-time high
- $130.00 · Mar 2023
- All-time low
- $0.39 · Sep 2025
- Return since IPO
- -91.2%
- Beta
- 0.57
- Book value / share
- $24.07
- Price / book
- 0.03
About LakeShore Biopharma Co., Ltd
LakeShore Biopharma Co., Ltd was a biopharmaceutical company that researched, made and sold vaccines and therapeutic biologics for infectious diseases and cancer. Its marketed product was YSJA, a conventional rabies vaccine.
Pipeline programs included PIKA, a rabies vaccine in phase I/III and preclinical trials; PIKA YS-ON-001, an immuno-oncology candidate in phase I for pancreatic and liver cancer; PIKA YS-HBV-001, a hepatitis B vaccine in phase I; and PIKA YS-HBV-002, a preclinical immune therapy for chronic HBV. A PIKA influenza vaccine was also in preclinical work.
Founded in 1994 and based in Beijing, China, the company was called YS Biopharma Co., Ltd. until May 2024. Its stock was delisted from the Nasdaq in November 2025, with the last trade on November 21, 2025 at $0.83.
- Exchange (former)
- Nasdaq
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Beijing
- Employees
- 758
- IPO date
- March 16, 2023
- Delisted
- November 21, 2025
- SEC CIK
- 1946399
LakeShore Biopharma Co. financials before the delisting
The last 5 fiscal years LakeShore Biopharma Co. reported as a public company, fiscal year ending March.
LSB revenue and net income
LSB earnings per share
LSB annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2025 | $614.96M | −$100.0M | — |
| FY2024 | $573.42M | −$433.5M | −$27.98 |
| FY2023 | $687.20M | −$145.5M | — |
| FY2022 | $502.95M | −$236.7M | $4.17 |
| FY2021 | $257.02M | −$191.8M | — |
Net income is GAAP. EPS is adjusted (non-GAAP) EPS, as reported.
LakeShore Biopharma Co. stock FAQ
What happened to LakeShore Biopharma Co. stock?
LakeShore Biopharma was delisted from the Nasdaq in November 2025. The final close was $0.83 on November 21, 2025.
Can I still buy LSB stock?
No. LSB is no longer listed on the Nasdaq or any other U.S. exchange; it was removed on November 21, 2025.
What was the last price of LSB?
LSB last closed at $0.83 on November 21, 2025, which valued the company at about $34.21M.
How did LakeShore Biopharma Co. do in its last full fiscal year?
In fiscal 2025, its last full year as a public company, LakeShore Biopharma Co. reported revenue of $614.96M and net income of −$100.0M.
When did LakeShore Biopharma Co. go public?
LakeShore Biopharma Co. shares started trading on March 16, 2023.
LSB no longer trades, so there is no live quote. The information on this page is for reference only and is not investment advice; see our disclaimer.